An observational study in Coronary Artery Disease and Systemic Inflammation, sponsored by Bursa Yuksek Ihtisas Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Bursa Yuksek Ihtisas Training and Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies in Coronary Artery Disease with a site in Turkey — 33 open to participants now, 42 under way, 4 of them phase 3. Coronary Artery Disease · Turkey.
Among the 137 studies in Coronary Artery Disease with a site in Turkey, this one is the 49th largest by enrollment of the 66 observational ones that give a count, is one of 25 that started in 2026, is one of 66 observational ones, and was the 130th registered.
4,862 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →33 of the 137 studies in Coronary Artery Disease with a site in Turkey are open now. Recruiting first, the newest first:
Adiyaman University · Sites in Turkey
Ages 18+
Elzem SEN · Sites in Turkey
Ages 18–80
Elzem SEN · Sites in Turkey
Ages 18–80
TC Erciyes University · Sites in Turkey
Ages 18–50 · Women only
Uludag University · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 30 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 11 · Phase 4 1
First in 2004; this study’s year is marked. 25 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is below the median of 326 across 1,689 observational studies indexed under Coronary Artery Disease.
Median enrollment 70 across the 71 interventional studies, 167 across the 66 observational. Of the 82 that completed or were terminated, 10 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 137 have an industry lead sponsor. The 10 most frequent:
Bursa Yuksek Ihtisas Training and Research Hospital is the lead sponsor of 53 studies on the registry; 23 are open to participants now.
Bursa Yuksek Ihtisas Training and Research Hospital has 4 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
17 of the studies in Coronary Artery Disease with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07444697Kırıkkale University"Erectile Function After PCI in MI and Non-MI Patients" | 2026-11 |
| NCT07768020Munzur UniversityEffect of Eye Mask Use on Sleep Quality and Delirium After CABG Surgery | 2026-11-15 |
| NCT07722637TC Erciyes UniversityThe Effect of Cardiac Rehabilitation on Ferroptosis in Patients With Coronary Artery Disease | 2026-11-15 |
| NCT07051473Istanbul University - CerrahpasaRelationship Between Coronary CT Angiography Findings and Prognosis Of Patients Undergoing PCI | 2026-12 |
| NCT07825376Abant Izzet Baysal UniversityBranching Scenario-Based Education in Coronary Artery Disease | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 137 studies in Coronary Artery Disease with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational study evaluates the effects of minimally invasive extracorporeal circulation (MIECC) and conventional cardiopulmonary bypass on systemic inflammatory response in patients undergoing coronary artery bypass graft surgery. Adult patients undergoing elective coronary artery bypass surgery will be observed according to the extracorporeal circulation technique used during surgery. Systemic inflammation will be assessed using routinely available hematologic inflammatory indices, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). These parameters will be evaluated preoperatively, at postoperative 6 hours, at postoperative 24 hours, and at hospital discharge. The study will also evaluate selected perioperative and postoperative clinical outcomes in order to compare the inflammatory response associated with MIECC and conventional extracorporeal circulation.
Coronary artery bypass graft surgery performed with cardiopulmonary bypass is associated with activation of systemic inflammatory pathways. Contact of blood with the extracorporeal circuit, surgical trauma, ischemia-reperfusion injury, and perioperative factors may contribute to this response. Minimally invasive extracorporeal circulation systems are designed to reduce blood-air contact, circuit surface area, and hemodilution and may therefore attenuate the inflammatory response compared with conventional cardiopulmonary bypass.
In this prospective observational study, patients undergoing elective coronary artery bypass graft surgery will be evaluated according to whether minimally invasive extracorporeal circulation or conventional extracorporeal circulation is used during surgery. No treatment assignment will be made by the study protocol.
Inflammatory response will be assessed using neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index calculated from routinely obtained laboratory measurements. Measurements will be evaluated preoperatively, at 6 hours after surgery, at 24 hours after surgery, and at hospital discharge. Perioperative variables and postoperative clinical outcomes will also be recorded for comparison between the two groups.
Adult patients aged 30-70 years undergoing elective coronary artery bypass graft surgery with either minimally invasive extracorporeal circulation or conventional cardiopulmonary bypass at Bursa Yuksek Ihtisas Training and Research Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergoing coronary artery bypass graft surgery using minimally invasive extracorporeal circulation (MIECC) as part of routine clinical care.
Procedure: Minimally Invasive Extracorporeal Circulation
Patients undergoing coronary artery bypass graft surgery using conventional cardiopulmonary bypass as part of routine clinical care.
Procedure: Conventional Cardiopulmonary Bypass
Use of a minimally invasive extracorporeal circulation system during coronary artery bypass graft surgery as part of routine clinical care.
Use of conventional cardiopulmonary bypass during coronary artery bypass graft surgery as part of routine clinical care.
Neutrophil-to-Lymphocyte Ratio (NLR)
NLR will be calculated from routine complete blood count values by dividing the absolute neutrophil count by the absolute lymphocyte count. Values will be compared between the MIECC and conventional cardiopulmonary bypass groups.
Time frame: Preoperative baseline, 6 hours after surgery, 24 hours after surgery, and on the morning of hospital discharge, an average of 6 days after surgery.
Platelet-to-Lymphocyte Ratio (PLR)
PLR will be calculated from routine complete blood count values by dividing the platelet count by the absolute lymphocyte count. Values will be compared between the MIECC and conventional cardiopulmonary bypass groups.
Time frame: Preoperative baseline, 6 hours after surgery, 24 hours after surgery, and on the morning of hospital discharge, an average of 6 days after surgery.
Systemic Immune-Inflammation Index (SII)
SII will be calculated as neutrophil count × platelet count / lymphocyte count using routine complete blood count values. Values will be compared between the MIECC and conventional cardiopulmonary bypass groups.
Time frame: Preoperative baseline, 6 hours after surgery, 24 hours after surgery, and on the morning of hospital discharge, an average of 6 days after surgery.
Plan to share: No — Individual participant data will not be shared because data sharing was not included in the approved study protocol or informed consent process.
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Sep 2026, 7 months.
Of 636 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's 7 months is below that.
Counting every sponsor, half of 761 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
Primary completion moved twice since we started tracking on Sep 25, 2026: Dec 2026 → Sep 2026, last on Oct 20, 2026.
Completion moved twice since we started tracking on Sep 25, 2026: Jan 2027 → Oct 2026, last on Oct 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bursa Yuksek Ihtisas Training and Research Hospital